Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States
- PMID: 21114482
- DOI: 10.1111/j.1365-2141.2010.08469.x
Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States
Abstract
Intracranial haemorrhage (ICH) is the most serious type of bleeding for patients with haemophilia. Prior published reports regarding ICH predate the widespread provision of prophylaxis. Our study objectives were to determine risk factors for ICH and whether prophylaxis reduces ICH occurrence. We performed a nested case-control study of persons with haemophilia, ≥2 years of age enrolled in the Centers for Disease Control and Prevention Universal Data Collection project. Of 10 262 patients 199 (1·9%) experienced an ICH for an incidence rate of 390/10⁵ patient years. Head trauma was reported in 44% (88/199). ICH mortality was 19·6% (39/199). Significant risk factors for ICH included a high titre inhibitor [odds ratio (OR) = 4·01, 95% confidence interval (2·40-6·71)], prior ICH [OR = 3·62 (2·66-4·92)] and severe haemophilia [OR = 3·25 (2·01-5·25)]. Prophylaxis was associated with a significant risk reduction for ICH occurrence in patients with severe haemophilia who were negative for human immunodeficiency virus or an inhibitor, with an OR of 0·52 (0·34-0·81) and 0·50 (0·32-0·77) respectively. The most significant risk factors for ICH included the presence of an inhibitor, prior ICH, severity of haemophilia and reported head trauma. This is the first study to demonstrate that prescribed prophylaxis conferred a protective effect against ICH in patients with uncomplicated severe disease.
Published 2010. This article is a US Government work and is in the public domain in the USA.
Similar articles
-
Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors.Haemophilia. 2012 Jan;18(1):39-45. doi: 10.1111/j.1365-2516.2011.02611.x. Epub 2011 Jul 14. Haemophilia. 2012. PMID: 21752159
-
Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.Haemophilia. 2009 Jan;15(1):78-82. doi: 10.1111/j.1365-2516.2008.01823.x. Epub 2008 Aug 12. Haemophilia. 2009. PMID: 18700841
-
The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.Haemophilia. 2008 Sep;14(5):923-30. doi: 10.1111/j.1365-2516.2008.01810.x. Epub 2008 Jul 14. Haemophilia. 2008. PMID: 18637844
-
Intracranial haemorrhage in haemophilia A and B.Br J Haematol. 2008 Feb;140(4):378-84. doi: 10.1111/j.1365-2141.2007.06949.x. Epub 2007 Dec 13. Br J Haematol. 2008. PMID: 18081890 Review.
-
[Prophylaxis in patients with haemophilia complicated by inhibitors].Pol Merkur Lekarski. 2011 Mar;30(177):211-4. Pol Merkur Lekarski. 2011. PMID: 21545000 Review. Polish.
Cited by
-
Risk of Intracranial Hemorrhage in Persons with Hemophilia A in the United States: Real-World Retrospective Cohort Study Using the ATHNdataset.J Blood Med. 2024 Apr 24;15:191-205. doi: 10.2147/JBM.S443380. eCollection 2024. J Blood Med. 2024. PMID: 38699197 Free PMC article.
-
Clinical and treatment characteristics of infants and toddlers less than 2 years of age with hemophilia.Blood Adv. 2024 Jun 11;8(11):2707-2717. doi: 10.1182/bloodadvances.2023012486. Blood Adv. 2024. PMID: 38547443 Free PMC article.
-
Nonacog beta pegol prophylaxis in children with hemophilia B: safety, efficacy, and neurodevelopmental outcomes for up to 8 years.Res Pract Thromb Haemost. 2024 Feb 8;8(2):102341. doi: 10.1016/j.rpth.2024.102341. eCollection 2024 Feb. Res Pract Thromb Haemost. 2024. PMID: 38516633 Free PMC article.
-
Emicizumab Prophylaxis in Patients with Severe Hemophilia A: Insights from A Resource Limited Country.Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296231224357. doi: 10.1177/10760296231224357. Clin Appl Thromb Hemost. 2024. PMID: 38166474 Free PMC article.
-
Neurological Complications Associated with Hereditary Bleeding Disorders.Curr Neurol Neurosci Rep. 2023 Nov;23(11):751-767. doi: 10.1007/s11910-023-01313-y. Epub 2023 Oct 21. Curr Neurol Neurosci Rep. 2023. PMID: 37864642 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

